Recombinant Anti-CD44 x Anti-CR3 Bispecific Antibody (scFv-Fc) is formed by fusing two different scFv fragments to the hinge and Fc regions, in which the Fc region are engineered by KIH. Two of scFv moiety has the antibody variable domain of either anti-CD44 specificity or anti-CR3 specificity, which produces bivalent IgG-like molecules with desired characteristics of intact antibodies. This BsAb can recruit macrophages to tumor cells. It is designed for the research of Glioblastoma; Squamous cancer therapy.
Welcome! For price inquiries, we will get back to you as soon as possible.
INQUIRY